Home » Stocks » EGRX

Eagle Pharmaceuticals, Inc. (EGRX)

Stock Price: $47.84 USD 0.18 (0.38%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 627.61M
Revenue (ttm) 183.03M
Net Income (ttm) 14.44M
Shares Out 13.07M
EPS (ttm) 1.06
PE Ratio 45.09
Forward PE 9.98
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $47.84
Previous Close $47.66
Change ($) 0.18
Change (%) 0.38%
Day's Open 48.00
Day's Range 46.87 - 48.00
Day's Volume 56,699
52-Week Range 36.48 - 53.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug and Administration (“FDA”) has maintained Priorit...

1 month ago - Business Wire

OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

Other stocks mentioned: EAF, OEG, RARE, TELA
1 month ago - Zacks Investment Research

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has responded to the Complete Response Letter (“CRL”) for its Abbrevi...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciar...

1 month ago - Newsfile Corp

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - May 14, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary...

2 months ago - Newsfile Corp

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

2 months ago - Business Wire

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share decreased 71.43% year over year to $0.24, which missed the e...

2 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three months ended March 31, 2021. Business and Rec...

2 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM RI (50ml) liquid formulation has been filed with the Pharmaceu...

2 months ago - Business Wire

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Directors. Dr. B...

2 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2)...

2 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial results on Mon...

2 months ago - Business Wire

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 100.00% year over year to $0.96, which may not com...

4 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, an...

4 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial...

5 months ago - Business Wire

The FDA has issued a complete response letter (CRL) for Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) abbreviated marketing application seeking vasopressin approval.

5 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete resp...

5 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District ...

5 months ago - Business Wire

NEWARK, N.J., Jan. 28, 2021 /PRNewswire/ -- SEEDS – Access Changes Everything (SEEDS) is pleased to announce a new, multi-year partnership with Eagle Pharmaceuticals that will provide educational fundin...

5 months ago - PRNewsWire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District o...

6 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

6 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company's pre-recorded presentation at the Piper Sandler 32nd Annual...

8 months ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Bus...

8 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced four additions to its clinical, formulations and commercialization leadership...

8 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Mon...

8 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated share repu...

10 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio”), has re...

10 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

10 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

11 months ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were flat in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

11 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

11 months ago - Business Wire

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a uni...

1 year ago - Business Wire

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.

1 year ago - Benzinga

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals stock popped Thursday after the pharmaceutical company said its hyperthermia drug, Ryanodex, showed promise as a potential coronavirus treatment in a laboratory test. The post Cov...

1 year ago - Investors Business Daily

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 37.14% and 8.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About EGRX

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and m... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Scott Tarriff
Employees
106
Stock Exchange
NASDAQ
Ticker Symbol
EGRX
Full Company Profile

Financial Performance

In 2020, EGRX's revenue was $187.80 million, a decrease of -4.13% compared to the previous year's $195.89 million. Earnings were $11.99 million, a decrease of -16.24%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for EGRX stock is "Buy." The 12-month stock price forecast is 47.33, which is a decrease of -1.07% from the latest price.

Price Target
$47.33
(-1.07% downside)
Analyst Consensus: Buy